By |

Equities News

Company chart and information is provided by TradingView based on 15-minute-delayed data.


Profile

AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.

Contact Information

Website: www.allovir.com
Email: ir@allovir.com
Main Phone: +1 617 433-2605
Address: 139 Main Street
Address 2: Suite 500
State: MA
City / Town: Cambridge
Country: US
Postal Code: 02142

Issuer Information

Exchange: NGS
CEO: David Hallal
Employees: 53
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)(541714)

Equities News

(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume N/A 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares N/A EPS (TTM) N/A PE Ratio N/A Exchange N/A